- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
694 Cards in this Set
- Front
- Back
|
Full-term neonate of uneventful
delivery becomes mentally retarded and hyperactive and has a musty odor. |
PKU.
|
|
Stressed executive comes
home from work, consumes 7 or 8 martinis in rapid succession before dinner, and becomes hypoglycemic. mech? |
NADH increase prevents
gluconeogenesis by shunting pyruvate and oxaloacetate to lactate and malate. |
|
2-year-old girl has an ↑ in
abdominal girth, failure to thrive, and skin and hair depigmentation. |
Kwashiorkor.
|
|
Alcoholic develops a rash,
diarrhea, and altered mental status. |
low Vitamin B3 (pellagra).
|
|
51-year-old man has black spots
in his sclera and has noted that his urine turns black upon standing. |
Alkaptonuria.
|
|
25-year-old male complains
of severe chest pain and has xanthomas of his Achilles tendons. |
Familial hypercholesterolemia;
|
|
A woman complains of intense
muscle cramps and darkened urine after exercise. |
McArdle’s disease.
|
|
Two parents with albinism
have a son who is normal. . how |
Locus heterogeneity.
|
|
A 40-year-old man has chronic
pancreatitis with pancreatic insufficiency. What vitamins are likely deficient? |
A, D, E, and K.
|
|
Vitamins
name the fat solubles and quick functions |
Vitamin A—Vision
Vitamin D—Bone calcification —Ca2+ homeostasis Vitamin K—Clotting factors Vitamin E—Antioxidant |
|
Vitamins
name the water solubles with aka's |
B1 (thiamine: TPP)
B2 (riboflavin: FAD, FMN) B3 (niacin: NAD+) B5 (pantothenate: CoA) B6 (pyridoxine: PP) B12 (cobalamin) C (ascorbic acid) Biotin Folate |
|
Vitamins: water
soluble All wash out easily from body except |
B12 and folate
|
|
B-complex deficiencies often
result in |
dermatitis,
glossitis, and diarrhea. |
|
Vitamin A
aka |
retinol
|
|
Vitamin A (retinol)
Deficiency |
Night blindness, dry skin. increased suceptability to measles
|
|
Vitamin A (retinol)
Function |
Constituent of visual pigments (retinal).
|
|
Vitamin A (retinol)
Excess |
Arthralgias, fatigue, headaches, skin changes, sore throat, alopecia.
|
|
retinol
aka |
Vitamin A
|
|
Vitamin A (retinol)
source |
Found in leafy vegetables.
|
|
Vitamin A (retinol)
mnemonioc |
Retinol is vitamin A, so think
Retin-A (used topically for wrinkles and acne). |
|
Vitamin B
aka |
thiamine
|
|
thiamine
aka |
Vitamin B
|
|
Vitamin B1 (thiamine)
Deficiency |
Beriberi and Wernicke-Korsakoff syndrome. Seen in alcoholism and malnutrition.
Spell beriberi as Ber1Ber1. |
|
Vitamin B1 (thiamine)
Function |
In thiamine pyrophosphate, a cofactor for oxidative
decarboxylation of α-keto acids (pyruvate, α-ketoglutarate) and a cofactor for transketolase in the HMP shunt. |
|
Dry beriberi
vs Wet beriberi |
Dry beriberi––polyneuritis,
muscle wasting. Wet beriberi––high-output cardiac failure (dilated cardiomyopathy), edema. |
|
Vitamin B2
aka |
riboflavin
|
|
riboflavin
aka |
Vitamin B2
|
|
Vitamin B2 (riboflavin)
Deficiency |
The 2C’s.
Angular stomatitis, Cheilosis, Corneal vascularization. |
|
Vitamin B2 (riboflavin)
Function |
Cofactor in oxidation and reduction (e.g., FADH2).
"FAD and FMN are derived from riboFlavin (B2 = 2 ATP)" |
|
Vitamin B3
aka |
niacin
|
|
niacin
aka |
Vitamin B3
|
|
Vitamin B3 (niacin)
Deficiency |
Pellagra can be caused by Hartnup disease (↓ tryptophan absorption), malignant carcinoid syndrome (↑ tryptophanmetabolism), and INH (↓ vitamin B6).
Pellagra’s symptoms are the 3 D’s: Diarrhea, Dermatitis, Dementia (also beefy glossitis). |
|
Vitamin B3 (niacin)
Function |
Constituent of NAD+, NADP+ (used in redoxreactions). Derived from tryptophan using vitamin B6.
NAD derived from Niacin (B3 = 3 ATP). |
|
Diarrhea, Dermatitis,
Dementia (also beefy glossitis). |
Pellagra
|
|
Pellagra’s symptoms
|
the 3 D’s: Diarrhea, Dermatitis,
Dementia (also beefy glossitis). |
|
pantothenate
aka |
Vitamin B5
|
|
Vitamin B5
aka |
pantothenate
|
|
Vitamin B5 (pantothenate)
Deficiency |
Dermatitis, enteritis, alopecia, adrenal insufficiency.
|
|
Vitamin B5 (pantothenate)
Function |
Constituent of CoA (a cofactor for acyl transfers)
and component of fatty acid synthase. Pantothen-A is in Co-A. |
|
pyridoxine
aka |
Vitamin B6
|
|
Vitamin B6
aka |
pyridoxine
|
|
Vitamin B6 (pyridoxine)
Deficiency |
Convulsions, hyperirritability (deficiency inducible by INH and oral contraceptives),
peripheral neuropathy. |
|
Vitamin B6 (pyridoxine)
Function |
Converted to pyridoxal phosphate, a cofactor used in transamination (e.g., ALT and AST),
decarboxylation, and heme synthesis. |
|
Vitamin B12
aka |
cobalamin
|
|
cobalamin
aka |
Vitamin B12
|
|
Vitamin B12 (cobalamin)
Deficiency |
Macrocytic, megaloblastic anemia; neurologic
symptoms (optic neuropathy, subacute combined degeneration, paresthesia); glossitis. |
|
Function
|
Cofactor for homocysteine methylation
(transfers CH3 groups as methylcobalamin) and methylmalonyl-CoA handling. |
|
Vitamin B12 (cobalamin)
source and storage |
Found only in animal products.
Stored primarily in the liver. Very large reserve pool (several years). |
|
Vitamin B12 (cobalamin)
causes of deficiency |
Vitamin B12 deficiency is
usually caused by malabsorption (sprue, enteritis, Diphyllobothrium latum), lack of intrinsic factor (pernicious anemia), or absence of terminal ileum (Crohn’s disease). |
|
Vitamin B12 (cobalamin)
testing |
Use Schilling test to detect
deficiency. |
|
Vitamin B12 (cobalamin)
syntesized by |
Synthesized only by microorganisms.
|
|
schilling test rocess
|
the patient is given radiolabeled vitamin B12 to drink A normal result shows at least 5% of the radiolabelled vitamin B12 in the urine over the first 24 hours.
|
|
Folic acid
Deficiency |
Macrocytic, megaloblastic anemia (often no neurologic symptoms, as opposed to vitamin B12 deficiency).
|
|
Folic acid
Function |
Coenzyme (tetrahydrofolate) for 1-carbon
transfer; involved in methylation reactions. Important for the synthesis of nitrogenous bases in DNA and RNA. |
|
Folic acid
source |
FOLate from FOLiage.
|
|
what is PABA and implications
|
PABA is the folic acid
precursor in bacteria. Sulfa drugs and dapsone (antimicrobials) are PABA analogs. |
|
the folic acid
precursor in bacteria |
PABA
|
|
Most common vitamin deficiency in the United
States. |
Folic acid
|
|
Biotin
Deficiency |
Dermatitis, enteritis. Caused by antibiotic use,
ingestion of raw eggs. “AVIDin in egg whites AVIDly binds biotin.” |
|
Biotin
Function |
Cofactor for carboxylations:
1. Pyruvate → oxaloacetate 2. Acetyl-CoA → malonyl-CoA 3. Proprionyl-CoA → methylmalonyl-CoA |
|
Vitamin C (ascorbic acid)
Deficiency |
Scurvy––swollen gums, bruising, anemia, poor wound healing.
|
|
Vitamin C (ascorbic acid)
Function |
Necessary for hydroxylation of proline and lysine in
collagen synthesis. Facilitates iron absorption by keeping iron in Fe+2 reduced state (more absorbable) Necessary as a cofactor for dopamine →NE. |
|
Vitamin C (ascorbic acid)
role in collagen formation |
Vitamin C Cross-links
Collagen. Necessary for hydroxylation of proline and lysine in collagen synthesis. |
|
Vitamin D
different forms and locations |
D2 = ergocalciferol, consumed in milk.
D3 = cholecalciferol, formed in sun-exposed skin. 25-OH D3 = storage form. 1,25 (OH)2 D3 = active form. |
|
Vitamin D
Deficiency |
Rickets in children (bending bones), osteomalacia
in adults (soft bones), and hypocalcemic tetany. |
|
Vitamin D
Function |
↑ intestinal absorption of calcium and phosphate.
|
|
Vitamin D
Excess |
Hypercalcemia, loss of appetite, stupor. Seen in
sarcoidosis, a disease where the epithelioid macrophages convert vitamin D into its active form. |
|
Vitamin E
Deficiency |
Increased fragility of erythrocytes, neurodysfunction.
Vitamin E is for Erythrocytes. |
|
Vitamin E
Function |
Antioxidant (protects erythrocytes from hemolysis).
Vitamin E is for Erythrocytes. |
|
Vitamin K
Deficiency |
Neonatal hemorrhage with ↑ PT and ↑ aPTT but normal bleeding time,
|
|
Vitamin K
Function |
Catalyzes γ-carboxylation of glutamic acid residues
on various proteins concerned with blood clotting. |
|
Vitamin K
Deficiency who is most vulnerable and why |
because neonates have sterile intestines and are unable to synthesize
vitamin K. |
|
Vitamin K
source |
Synthesized by intestinal flora. Therefore, vitamin
K deficiency can occur after the prolonged use of broad-spectrum antibiotics. |
|
the vitamin K–dependent
clotting factors are |
II, VII, IX, X,
|
|
Zinc
deficiency |
Delayed wound healing, hypogonadism, ↓ adult hair (axillary, facial, pubic); may
predispose to alcoholic cirrhosis. |
|
Delayed wound healing, hypogonadism, ↓ adult hair (axillary, facial, pubic); may
predispose to alcoholic cirrhosis. |
Zinc
deficiency |
|
Night blindness, dry skin.
|
Vitamin A (retinol)
Deficiency |
|
Beriberi and Wernicke-Korsakoff syndrome
|
Vitamin B1 (thiamine)
Deficiency |
|
A, D, E, K. Absorption dependent on
|
gut (ileum) and pancreas.
|
|
Angular stomatitis, Cheilosis, Corneal
vascularization. |
Vitamin B2 (riboflavin)
Deficiency |
|
Dermatitis, enteritis, alopecia, adrenal insufficiency.
|
Vitamin B5 (pantothenate)
Deficiency |
|
Convulsions, hyperirritability (deficiency inducible by INH and oral contraceptives),
peripheral neuropathy. |
Vitamin B6 (pyridoxine)
Deficiency |
|
Macrocytic, megaloblastic anemia; neurologic
symptoms (optic neuropathy, subacute combined degeneration, paresthesia); glossitis. |
Vitamin B12 (cobalamin)
Deficiency |
|
Macrocytic, megaloblastic anemia (often no
neurologic symptoms, as opposed to vitamin B12 deficiency). |
Folic acid
Deficiency |
|
Dermatitis, enteritis. Caused by antibiotic use,
|
Biotin
Deficiency |
|
Increased fragility of erythrocytes, neurodysfunction.
|
Vitamin E
Deficiency |
|
Ethanol metabolism
limiting reagent |
NAD+ is the limiting reagent.
|
|
Disulfiram (Antabuse)
mech |
inhibits acetaldehyde dehydrogenase (acetaldehyde accumulates, contributing to hangover symptoms).
|
|
Disulfiram
aka |
Antabuse
|
|
Antabuse
|
Disulfiram
|
|
Ethanol hypoglycemia
mech |
Ethanol metabolism ↑ NADH/NAD+ ratio in liver, causing diversion of pyruvate to lactate and OAA to malate, thereby inhibiting gluconeogenesis
|
|
fatty change mech
|
↑ NADH/NAD+ ratio in liver with shunting away from glycolysis and toward fatty acid synthesis
|
|
Kwashiorkor
causes |
Kwashiorkor results from a
protein-deficient MEAL: Malabsorption Edema Anemia Liver (fatty) |
|
Kwashiorkor
|
protein malnutrition resulting in skin
lesions, edema, liver malfunction (fatty change). Clinical picture is small child with swollen belly. |
|
protein malnutrition resulting in skin lesions, edema, liver malfunction (fatty change).
Clinical picture is small child with swollen belly. |
Kwashiorkor
|
|
Marasmus
|
energy malnutrition resulting in
tissue and muscle wasting, loss of subcutaneous fat, and variable edema. |
|
energy malnutrition resulting in
tissue and muscle wasting, loss of subcutaneous fat, and variable edema. |
Marasmus
|
|
Chromatin
structure |
(−) charged DNA loops twice around nucleosome
core (2 each of the (+) charged H2A, H2B, H3, and H4) to form nucleosome bead.H1 ties nucleosomes together in a string (30-nm fiber). |
|
the only histone that is not
in the nucleosome core. |
H1 is
|
|
H1 is
|
the only histone that is not
in the nucleosome core. |
|
Heterochromatin
|
Condensed, transcriptionally inactive Chromatin
|
|
Condensed, transcriptionally inactive Chromatin
|
Heterochromatin
|
|
Less condensed, transcriptionally active Chromatin
|
Euchromatin
|
|
Euchromatin
|
Less condensed, transcriptionally active Chromatin
|
|
Nucleotides
ring number |
Purines (A, G) have 2 rings. Pyrimidines (C, T, U)
have 1 ring. |
|
Deamination of ???? makes uracil.
|
cytosine
|
|
Deamination of cytosine makes ????.
|
uracil.
|
|
Amino acids necessary for purine
synthesis: |
Glycine
Aspartate Glutamine |
|
which Nucleotide
has a methyl |
Thymine
|
|
which Nucleotide
has a ketone |
Guanine
|
|
Nucleotides
which are which |
-Purines (A, G) PURe As Gold: PURines.
-Pyrimidines (C, T, U) CUT the PY (pie): PYrimidines. |
|
Nucleotides (base + ribose + phosphate) are linked by
|
3′-5′ phosphodiester bond.
|
|
Nucleotides are made of what three things
|
base + ribose + phosphate
|
|
Nucleotides
Transition vs. transversion |
Transition-Substituting purine for purine or pyrimidine for
pyrimidine. ( TransItion = Identical type.) Transversion Substituting purine for pyrimidine or visa versa. (TransVersion = conVersion between types). |
|
Genetic code features and exceptions
Unambiguous |
Each codon specifies only one amino acid.
no exceptions |
|
Genetic code features and exceptions
Degenerate/redundant |
More than one codon may code for the same
amino acid. Methionine encoded by only one codon. |
|
Genetic code features and exceptions
Commaless, nonoverlapping |
Read from a fixed starting point as a continuous
sequence of bases. Some viruses are an exception. |
|
Genetic code features and exceptions
Universal |
Genetic code is conserved throughout evolution.
Exceptions include mitochondria, archaebacteria, Mycoplasma, and some yeasts. |
|
Mutations in DNA
Silent |
Same aa, often base change in 3rd position of
codon (tRNA wobble). |
|
Mutations in DNA
Same aa, often base change in 3rd position of codon (tRNA wobble). |
Silent
|
|
Mutations in DNA
Missense |
Changed aa (conservative––new aa is similar
in chemical structure). |
|
Mutations in DNA
Changed aa (conservative––new aa is similar in chemical structure). |
Missense
|
|
Mutations in DNA
Nonsense |
Change resulting in early stop codon.
|
|
Mutations in DNA
Change resulting in early stop codon. |
Nonsense
|
|
Mutations in DNA
Frame shift |
Change resulting in misreading of all nucleotides
downstream, usually resulting in a truncated protein. |
|
Mutations in DNA
Change resulting in misreading of all nucleotides downstream, usually resulting in a truncated protein. |
Frame shift
|
|
point Mutations in DNA
Severity of damage |
Severity of damage: nonsense
> missense > silent. |
|
DNA replication and DNA polymerases
who has multiple origins of replication. |
Eukaryotic genome
|
|
DNA replication and DNA polymerases
Eukaryotes Replication begins at |
Replication begins at a consensus sequence of
AT-rich base pairs. |
|
DNA replication and DNA polymerases
who has Single origin of replication |
Prokaryotes
|
|
DNA replication and DNA polymerases
Create a nick in the helix to relieve supercoils. |
DNA
topoisomerases |
|
DNA replication and DNA polymerases
function/activity of DNA topoisomerases |
Create a nick in the helix to
relieve supercoils. |
|
DNA replication and DNA polymerases
Makes an RNA primer on which DNA polymerase III can initiate replication. |
Primase
|
|
DNA replication and DNA polymerases
function/activity of Primase |
Makes an RNA primer on which DNA
polymerase III can initiate replication. |
|
DNA replication and DNA polymerases
Elongates the chain by adding deoxynucleotides to the 3′ end until it reaches primer of preceding fragment. 3′→ 5′ exonuclease activity “proofreads” each added nucleotide. |
DNA polymerase
III |
|
DNA replication and DNA polymerases
function/activity of DNA polymerase III |
Elongates the chain by adding
deoxynucleotides to the 3′ end until it reaches primer of preceding fragment. 3′→ 5′ exonuclease activity “proofreads” each added nucleotide. |
|
DNA replication and DNA polymerases
Degrades RNA primer and fills in the gap with DNA. |
DNA polymerase I
|
|
DNA replication and DNA polymerases
function/activity of DNA polymerase I |
Degrades RNA primer and fills in the gap
with DNA. |
|
DNA replication and DNA polymerases
Seals. |
DNA ligase
|
|
DNA replication and DNA polymerases
function/activity of DNA ligase |
Seals.
|
|
??????? has
5′→ 3′ synthesis and proofreads with 3′→ 5′ exonuclease. |
DNA polymerase III
|
|
??????? excises
RNA primer with 5′→ 3′ exonuclease. |
DNA polymerase I
|
|
DNA repair
Nucleotide excision repair |
Specific endonucleases release the oligonucleotide-
containing damaged bases; DNA polymerase and ligase fill and reseal the gap, respectively. |
|
DNA repair
Specific endonucleases release the oligonucleotide- containing damaged bases; DNA polymerase and ligase fill and reseal the gap, respectively. |
Nucleotide excision
repair |
|
DNA repair
Base excision repair |
Specific glycosylases recognize and remove damaged
bases, AP endonuclease cuts DNA at apyrimidinic site, empty sugar is removed, and the gap is filled and resealed. |
|
DNA repair
Specific glycosylases recognize and remove damaged bases, AP endonuclease cuts DNA at apyrimidinic site, empty sugar is removed, and the gap is filled and resealed. |
Base excision repair
|
|
DNA repair
mutation in Nucleotide excision repair |
Mutated in xeroderma
pigmentosa (dry skin with melanoma and other cancers). |
|
DNA repair
mutation in xeroderma pigmentosa |
Nucleotide excision
repair |
|
DNA repair
Base excision repair |
Specific glycosylases recognize and remove damaged
bases, AP endonuclease cuts DNA at apyrimidinic site, empty sugar is removed, and the gap is filled |
|
DNA repair
Specific glycosylases recognize and remove damaged bases, AP endonuclease cuts DNA at apyrimidinic site, empty sugar is removed, and the gap is filled |
Base excision repair
|
|
Mismatch repair
|
Unmethylated, newly synthesized string is recognized, M
mismatched nucleotides are remove, and the gap is filled and resealed. |
|
DNA repair
Unmethylated, newly synthesized string is recognized, M mismatched nucleotides are remove, and the gap is filled and resealed. |
Mismatch repair
|
|
DNA repair
Mutation in hereditary nonpolyposis colon cancer. |
Mismatch repair
|
|
DNA repair
Nonhomologous end joining |
Brings together two ends of DNA fragments. No requirement for homology.
|
|
DNA repair
Brings together two ends of DNA fragments. No requirement for homology. |
Nonhomologous
end joining |
|
DNA/RNA
synthesis direction |
DNA and RNA are both synthesized 5′→ 3′.
Remember that the 5′ of the incoming nucleotide bears the triphosphate (energy source for bond). The 3′ hydroxyl of the nascent chain is the target. |
|
protein synth
synthesis direction |
Protein synthesis also proceeds
in the 5′ to 3′ direction. Amino acids are linked N to C. |
|
Types of RNA
and descriptions |
Massive, Rampant, Tiny.
mRNA is the largest type of RNA. rRNA is the most abundant type of RNA. tRNA is the smallest type of RNA. |
|
RNA polymerases
Eukaryotes I,II,III |
RNA polymerase I makes rRNA.
RNA polymerase II makes mRNA. RNA polymerase III makes tRNA. |
|
RNA polymerases
Prokaryotes |
RNA polymerase (multisubunit complex) makes
all 3 kinds of RNA. |
|
α-amanitin
|
found in death cap mushrooms.
inhibits RNA polymerase II. |
|
found in death cap mushrooms.
inhibits RNA polymerase II. |
α-amanitin
|
|
RNA polymerases
proofreading |
No proofreading function, but can initiate chains.
|
|
???? opens DNA at promoter site
|
RNA polymerase II opens DNA at promoter site
|
|
mRNA initiation
codons |
AUG (or rarely GUG).
AUG inAUGurates protein synthesis. |
|
mRNA stop codons
|
UGA = U Go Away.
UAA = U Are Away. UAG = U Are Gone. |
|
Promoter
|
Site where RNA polymerase and multiple other
transcription factors bind to DNA upstream from gene locus (AT-rich upstream sequence with TATA and CAAT boxes). |
|
Site where RNA polymerase and multiple other
transcription factors bind to DNA upstream from gene locus (AT-rich upstream sequence with TATA and CAAT boxes). |
Promoter
|
|
Stretch of DNA that alters gene expression by binding
transcription factors. May be located close to, far from, or even within (in an intron) the gene whose expression it regulates. |
Enhancer
|
|
Enhancer
|
Stretch of DNA that alters gene expression by binding
transcription factors. May be located close to, far from, or even within (in an intron) the gene whose expression it regulates. |
|
Promoter mutation commonly
results in |
dramatic ↓ in
amount of gene transcribed. |
|
Site where negative regulators (repressors) bind.
|
Operator
|
|
Operator
|
Site where negative regulators (repressors) bind.
|
|
Introns vs.
exons |
Exons contain the actual genetic information coding for protein.
Introns are intervening noncoding segments of DNA. |
|
Splicing of mRNA
steps |
➀ Primary transcript combines with snRNPs to form spliceosome.
➁ Lariat-shaped intermediate is generated. ➂ Lariat is released to remove intron precisely and join two exons. |
|
RNA processing
(eukaryotes) where |
Occurs in nucleus. After transcription:
|
|
RNA processing
(eukaryotes) steps |
1. Capping on 5′ end (7-methyl-G)
2. Polyadenylation on 3′ end (≈ 200 A’s) 3. Splicing out of introns |
|
RNA processing
(eukaryotes) names |
Initial transcript is called heterogeneous nuclear
RNA (hnRNA). Capped and tailed transcript is called mRNA. |
|
Only ???????? RNA is
transported out of the nucleus. |
processed
|
|
RNA processing
(eukaryotes) wrt transport |
Only processed RNA is
transported out of the nucleus. |
|
tRNA
Structure |
75–90 nucleotides, cloverleaf form, anticodon end is opposite 3′ aminoacyl end. All
tRNAshave CCA at 3′ end where aa's are bound |
|
tRNA Charging
|
Aminoacyl-tRNA synthetase (1 per aa, uses ATP)
|
|
where is error protection in protein synthesis
|
in TRNA charging. once aa is on there it will put on a wrong aa
|
|
Protein synthesis
Initiation |
Initiation factors (IFs) help assemble the 30S
ribosomal subunit with the initiator tRNA, are released when the mRNA and the ribosomal subunit assemble with the complex. |
|
Protein synthesis
elongation steps |
1. Aminoacyl tRNA binds to A site.
2. Peptidyltransferase catalyzes peptide bond formation, transfers growing polypeptide to ami acid in A site. 3. Ribosome advances three nucleotides toward 3′ end of RNA, moving peptidyl RNA to P site. |
|
Protein synthesis
A site |
A site = incoming Aminoacyl
tRNA. |
|
Protein synthesis
P site |
P site = accommodates growing
Peptide. |
|
Protein synthesis
E site |
E site = holds Empty tRNA as
it Exits. |
|
Protein synthesis
ATP vs GTP |
ATP—tRNA Activation
(charging). GTP—tRNA Gripping and Going places (translocation). |
|
Posttranslational modifications
Trimming |
Removal of N- or C-terminal pro-peptides from zymogens to generate mature proteins.
|
|
Posttranslational modifications
Covalent alterations |
Phosphorylation, glycosylation, and hydroxylation.
|
|
Posttranslational modifications
Proteasomal degradation |
Attachment of ubiquitin to defective proteins to tag them for breakdown.
|
|
Cell cycle phases
shortest phase |
Mitosis
|
|
Cell cycle phases
Permanent cells what and examples |
Remain in G0, regenerate from stem cells.
Never go to G0, divide rapidly with a short G1. |
|
Cell cycle phases
Stable cells what and examples |
Enter G1 from G0 when stimulated.
Hepatocytes, lymphocytes. |
|
Cell cycle phases
Labile cells what and examples |
Never go to G0, divide rapidly with a short G1.
Bone marrow, gut epithelium, skin, hair follicles. |
|
Checkpoints control
transitions between phases. Regulated by |
cyclins, cdks, and
tumor suppressors. |
|
RER is the site of
|
synthesis of secretory (exported)
proteins and of N-linked oligosaccharide addition to many proteins. |
|
the site of synthesis of secretory (exported)
proteins and of N-linked oligosaccharide addition to many proteins. |
RER
|
|
Mucus-secreting goblet cells of
the small intestine and antibody-secreting plasma cells are rich in |
RER.
|
|
what cells are particularly rich in RER.
|
Mucus-secreting goblet cells of
the small intestine and antibody-secreting plasma cells |
|
SER is the site of
|
steroid synthesis and detoxification
of drugs and poisons. |
|
the site of steroid synthesis and detoxification
of drugs and poisons. |
SER
|
|
what cells are particularly rich in SER.
|
Liver hepatocytes and
steroid hormone–producing cells of the adrenal cortex |
|
Liver hepatocytes and
steroid hormone–producing cells of the adrenal cortex are rich in |
SER.
|
|
6 Functions of Golgi
apparatus |
1. Distribution center of proteins and lipids from
ER to the plasma membrane, lysosomes, and secretory vesicles 2. Modifies N-oligosaccharides 3. Adds O-oligosaccharides 4. Addition of mannose-6-phosphate 5. Proteoglycan assembly 6. Sulfation |
|
I-cell disease
mech |
failure of addition of mannose-6-phosphate to
lysosome proteins, enzymes are secreted outside the cell instead of being targeted to the lysosome. |
|
failure of addition of mannose-6-phosphate to
lysosome proteins, enzymes are secreted outside the cell instead of being targeted to the lysosome. |
I-cell disease:
|
|
I-cell disease
clinical findings |
Characterized by coarse facial
features, clouded corneas, restricted joint movement, and high plasma levels of lysosomal enzymes. Often fatal in childhood. |
|
Characterized by coarse facial
features, clouded corneas, restricted joint movement, and high plasma levels of lysosomal enzymes. Often fatal in childhood. |
I-cell disease
clinical findings |
|
Vesicular trafficking proteins:
COP I |
Retrograde,
Golgi → ER. |
|
Vesicular trafficking proteins:
Retrograde, Golgi → ER. |
COP I
|
|
Vesicular trafficking proteins:
COP II |
Anterograde,
RER → cis-Golgi. |
|
Vesicular trafficking proteins:
Anterograde, RER → cis-Golgi. |
COP II
|
|
Vesicular trafficking proteins:
Clathrin |
trans-Golgi →
lysosomes, plasma membrane → endosomes (receptor-mediated endocytosis). |
|
Vesicular trafficking proteins:
trans-Golgi → lysosomes, plasma membrane → endosomes (receptor-mediated endocytosis). |
Clathrin
|
|
Microtubule
structure |
Cylindrical structure 24 nm in diameter and of variable
length. A helical array of polymerized dimers of α- and β-tubulin (13 per circumference). Each dimer has 2 GTP bound. |
|
Microtubule
functions |
has 2 GTP bound. Incorporated into flagella, cilia,
mitotic spindles.Microtubules are also involved in slow axoplasmic transport in neurons. |
|
Microtubule
speeds |
Grows slowly, collapses quickly.
|
|
Drugs that act on microtubules:
|
1. Mebendazole/thiabendazole
(antihelminthic) 2. Taxol (anti–breast cancer) 3. Griseofulvin (antifungal) 4. Vincristine/vinblastine (anti-cancer) 5. Colchicine (anti-gout) |
|
is due to a microtubule
polymerization defect resulting in ↓ phagocytosis. |
Chédiak-Higashi syndrome
|
|
Chédiak-Higashi syndrome
mech |
is due to a microtubule
polymerization defect resulting in ↓ phagocytosis. |
|
Cilia structure
|
9 + + 2 arrangement of microtubules.
Dynein is an ATPase that links peripheral 9 doublets and causes bending of cilium by differential sliding of doublets. |
|
9 + + 2 arrangement of microtubules.
Dynein is an ATPase that links peripheral 9 doublets and causes bending of cilium by differential sliding of doublets. |
Cilia structure
|
|
Molecular motors
Dynein = Kinesin = |
Molecular motors
Dynein = retrograde. Kinesin = anterograde. |
|
Molecular motors
retrograde. anterograde. |
Molecular motors
Dynein = retrograde. Kinesin = anterograde. |
|
Kartagener’s syndrome
mech and clinical findings |
Immotile cilia due to a dynein arm defect. Results in male and female infertility (sperm
immotile), bronchiectasis, and recurrent sinusitis (bacteria and particles not pushed out); associated with situs inversus. |
|
Plasma membrane composition with %'s
|
Asymmetric fluid bilayer.
Contains cholesterol (~50%), phospholipids (~50%), sphingolipids, glycolipids, and proteins. |
|
Plasma membrane wrt cholesterol
|
High cholesterol or long saturated fatty acid content → increased melting temperature.
|
|
Phosphatidylcholine
aka |
lecithin
|
|
lecithin
aka |
Phosphatidylcholine
|
|
Phosphatidylcholine
(lecithin) function |
Major component of RBC membranes, of myelin, bile, and surfactant (DPPC–
dipalmitoyl PC). Used in esterification of cholesterol (LCAT is lecithin-cholesterol acyltransferase). |
|
Major component of RBC membranes, of myelin, bile, and surfactant
|
Phosphatidylcholine
(lecithin) |
|
Na+-K+ATPase
location and orientation |
Na+-K+ATPase is located in the plasma membrane
with ATP site on cytoplasmic side. For each ATP consumed, 3 Na+ go out and 2 K+ come in. |
|
Ouabain
mech |
inhibits Na+-K+ATPase by binding to K+ site.
|
|
inhibits Na+-K+ATPase by binding to K+ site
|
Ouabain
|
|
Na+-K+ATPase
wrt cardiac glycosides |
Cardiac glycosides (digoxin,
digitoxin) also inhibit the Na+-K+ATPase, causing ↑ cardiac contractility. 2K+ |
|
Most abundant protein in the human body.
|
Collagen
|
|
Collagen
how common |
Most abundant protein in the human body.
|
|
Collagen
general function |
Organizes and strengthens extracellular matrix.
|
|
Organizes and strengthens extracellular matrix.
|
Collagen
|
|
Collagen Types
Type I |
(90%)––Bone, Skin, Tendon, dentin, fascia, cornea, late wound repair.
|
|
Collagen Types
Bone, Skin, Tendon, dentin, fascia, cornea, late wound repair. |
Type I
|
|
Collagen Types
Type II |
Cartilage (including hyaline), vitreous body, nucleus pulposus.
Type II: carTWOlage. |
|
Collagen Types
Cartilage (including hyaline), vitreous body, nucleus pulposus. |
Type II
Type II: carTWOlage. |
|
Collagen Types
Type III (Reticulin) |
skin, blood vessels, uterus,
fetal tissue, granulation tissue. |
|
Collagen Types
skin, blood vessels, uterus, fetal tissue, granulation tissue. |
Type III (Reticulin)
|
|
Collagen Types
Type IV |
Basement membrane or basal lamina.
Type IV: Under the floor (basement membrane).. |
|
Collagen Types
Basement membrane or basal lamina. |
Type IV
Type IV: Under the floor (basement membrane). |
|
Collagen
Type III aka |
Reticulin
|
|
Reticulin aka
|
Type III Collagen
|
|
Collagen synthesis and structure
steps inside fibroblasts and where inside of them |
1. Synthesis (RER)
2. Hydroxylation (ER) 3. Glycosylation (Golgi) 4. Exocytosis |
|
Collagen synthesis and structure
steps outside fibroblasts |
5. Proteolytic
processing 6. Cross-linking |
|
Collagen synthesis and structure
Synthesis (RER) |
Translation of collagen α chains (preprocollagen)—
usually Gly-X-Y polypeptide (X and Y are proline, hydroxyproline, or hydroxylysine). |
|
Collagen synthesis and structure
Translation of collagen α chains (preprocollagen)— usually Gly-X-Y polypeptide (X and Y are proline, hydroxyproline, or hydroxylysine). |
1. Synthesis (RER)
|
|
Collagen synthesis and structure
Hydroxylation of specific proline and lysine residues (requires vitamin C). |
2. Hydroxylation
(ER) |
|
Collagen synthesis and structure
Hydroxylation (ER) |
Hydroxylation of specific proline and lysine
residues (requires vitamin C). |
|
Collagen synthesis and structure
Glycosylation of pro-α-chain lysine residues and formation of procollagen (triple helix of three collagen α chains). |
Glycosylation
(Golgi) |
|
Collagen synthesis and structure
Glycosylation (Golgi) |
Glycosylation of pro-α-chain lysine residues and
formation of procollagen (triple helix of three collagen α chains). |
|
Collagen synthesis and structure
Exocytosis of procollagen into extracellular space. |
4. Exocytosis
|
|
Collagen synthesis and structure
4. Exocytosis |
Exocytosis of procollagen into extracellular
space. |
|
Collagen synthesis and structure
5. Proteolytic processing |
Cleavage of terminal regions of procollagen
transforms it into insoluble tropocollagen. |
|
Collagen synthesis and structure
Cleavage of terminal regions of procollagen transforms it into insoluble tropocollagen. |
5. Proteolytic
processing |
|
Collagen synthesis and structure
6. Cross-linking |
Reinforcement of many staggered tropocollagen
molecules by covalent lysine-hydroxylysine cross-linkage (by lysyl oxidase) to make col- lagen fibrils. |
|
Collagen synthesis and structure
Reinforcement of many staggered tropocollagen molecules by covalent lysine-hydroxylysine cross-linkage (by lysyl oxidase) to make col- lagen fibrils. |
6. Cross-linking
|
|
Ehlers-Danlos syndrome
mech and clinical findings |
Faulty collagen synthesis (Type III is most frequently
affected (resulting in blood vessel instability) causing: 1. Hyperextensible skin 2. Tendency to bleed (easy bruising) 3. Hypermobile joints 4.Associated with berry aneurysms. |
|
Osteogenesis imperfecta
4 findings |
1. Multiple fractures
2. Blue sclerae 3. Hearing loss (abnormal middle ear bones) 4. Dental imperfections due to lack of dentition |
|
Osteogenesis imperfecta
worst type and findings |
Type II is fatal in utero or in
the neonatal period. |
|
5 Immunohistochemical stains
and associated cell types |
Vimentin - Connective tissue
Desmin - Muscle Cytokeratin - Epithelial cells Glial fibrillary acid proteins (GFAP) - Neuroglia Neurofilaments - Neurons |
|
Stretchy protein within lungs, large arteries, elastic
ligaments. |
Elastin
|
|
Elastin
what and where |
Stretchy protein within lungs, large arteries, elastic
ligaments. |
|
Elastin
structure |
Rich in proline and lysine, nonhydroxylated forms.
|
|
Elastin
wrt diseases |
Emphysema can be caused by
excess elastase activity. |
|
????? inhibits elastase.
|
α1-antitrypsin
|
|
α1-antitrypsin inhibits ??????
|
elastase.
|
|
Marfan’s syndrome is caused
by a defect in? |
fibrillin.
|
|
Metabolism sites
Mitochondria only |
Fatty acid oxidation (β-oxidation), acetyl-CoA production, Krebs cycle.
|
|
Metabolism sites
Cytoplasm only |
Glycolysis, fatty acid synthesis, HMP shunt, protein synthesis (RER), steroid synthesis
(SER). |
|
Metabolism sites
Both Mitochondria and Cytoplasm |
heme synthesis, urea cycle, Gluconeogenesis,
"HUGs take 2" |
|
Aerobic metabolism of glucose produces ???? via malate shuttle,
|
38 ATP
|
|
Aerobic metabolism of glucose produces ???? via G3P shuttle.
|
36
|
|
Aerobic metabolism of glucose produces 38 ATP via
|
malate shuttle
|
|
Aerobic metabolism of glucose produces 36 ATP via
|
G3P shuttle.
|
|
Anaerobic glycolysis produces ???? per glucose molecule.
|
only 2 net ATP
|
|
Activated carriers (what carries/what is carried by)
ATP |
Phosphoryl
|
|
Activated carriers (what carries/what is carried by)
Phosphoryl |
(ATP).
|
|
Activated carriers (what carries/what is carried by)
Electrons |
(NADH, NADPH, FADH2).
|
|
Activated carriers (what carries/what is carried by)
NADH, NADPH, FADH2 |
Electrons
|
|
Activated carriers (what carries/what is carried by)
Acyl |
(coenzyme A, lipoamide).
|
|
Activated carriers (what carries/what is carried by)
coenzyme A |
Acyl
|
|
Activated carriers (what carries/what is carried by)
lipoamide |
Acyl
|
|
Activated carriers (what carries/what is carried by)
CO2 |
biotin
|
|
Activated carriers (what carries/what is carried by)
biotin |
CO2
|
|
Activated carriers (what carries/what is carried by)
1-carbon units |
(tetrahydrofolates).
|
|
Activated carriers (what carries/what is carried by)
tetrahydrofolates |
1-carbon units
|
|
Activated carriers (what carries/what is carried by)
CH3 groups |
(SAM).
|
|
Activated carriers (what carries/what is carried by)
SAM |
CH3 groups
|
|
Activated carriers (what carries/what is carried by)
TPP |
Aldehydes
|
|
Activated carriers (what carries/what is carried by)
Aldehydes |
(TPP).
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
De novo pyrimidine synthesis |
Aspartate transcarbamylase (ATCase)
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Aspartate transcarbamylase (ATCase) |
De novo pyrimidine
synthesis |
|
Rate-determining enzymes of metabolic processes (process/enzyme)
De novo purine svnthesis |
Glutamine-PRPP amidotransferase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glutamine-PRPP amidotransferase |
De novo purine
svnthesis |
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glycolysis |
PFK-1
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
PFK-1 |
Glycolysis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
F 1,6-bisphosphotase (FBP-1) |
Gluconeogenesis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Gluconeogenesis |
F 1,6-bisphosphotase (FBP-1)
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
TCA cycle |
lsocitrate dehydrogenase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
lsocitrate dehydrogenase |
TCA cycle
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glycogen synthesis |
Glycogen synthase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glycogen synthase |
Glycogen synthesis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glycogenolysis |
Glycogen phosphorylase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glycogen phosphorylase |
Glycogenolysis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
HMP shunt |
Glucose-6-phosphate dehydrogenase (G6PD)
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Glucose-6-phosphate dehydrogenase (G6PD) |
HMP shunt
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Fatty acid synthesis |
Acetyl-CoA carboxylase (ACC)
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Acetyl-CoA carboxylase (ACC) |
Fatty acid synthesis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Fatty acid oxidation |
Carnitine a~~ltransferase I
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Carnitine a~~ltransferase I |
Fatty acid oxidation
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Ketogenesis |
HMG-CoA synthase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
HMG-CoA synthase |
Ketogenesis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
HMG-CoA reductase |
Cholesterol synthesis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Cholesterol synthesis |
HMG-CoA reductase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Heme synthesis |
ALA synthase
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
ALA synthase |
Heme synthesis
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Carbamoyl phosphate synthase I |
Urea cycle
|
|
Rate-determining enzymes of metabolic processes (process/enzyme)
Urea cycle |
Carbamoyl phosphate synthase I
|
|
ATP + methionine →
|
S-adenosyl-
methionine (SAM) |
|
SAM
function/regeneration |
SAM the methyl donor man.
SAM transfers methyl units. Regeneration of methionine (and thus SAM) is dependent on vitamin B12. |
|
Universal electron
acceptors |
Nicotinamides (NAD+, NADP+) and flavin
nucleotides (FAD+). |
|
NADPH is a product of
|
the HMP shunt.
|
|
NAD+ is generally used in
|
catabolic processes to
carry reducing equivalents away as NADH. |
|
NADPH is generally used in
|
anabolic processes (steroid
and fatty acid synthesis) as a supply of reducing equivalents. |
|
NADPH is used in:
|
1. Anabolic processes
2. Respiratory burst 3. P-450 |
|
?????is used in:
1. Anabolic processes 2. Respiratory burst 3. P-450 |
NADPH
|
|
Hexokinase
WRT locations, affinity, capacity, inhibition |
(ubiquitous)
High affinity, low capacity. Feedback inhibited by glucose-6- phosphate. |
|
Glucokinase
WRT locations, affinity, capacity, inhibition |
(liver)
Low affinity, high capacity. No feedback inhibition. |
|
Glucokinase
role |
Phosphorylates excess glucose
(e.g., after a meal) to sequester it in the liver. |
|
Phosphorylates excess glucose
(e.g., after a meal) to sequester it in the liver. |
Glucokinase
|
|
the most potent activator of
phosphofructokinase (how strong) |
F2,6BP
(overrides inhibition by ATP and citrate). |
|
Glycolytic enzyme deficiency
%'s |
Pyruvate kinase (95%), glucose phosphate (4%),
|
|
Glycolytic enzyme deficiency
clinical findings (why) |
Associated with hemolytic anemia.
RBCs metabolize glucose anaerobically (no mitochondria) and thus depend solely on glycolysis. |
|
Pyruvate dehydrogenase complex
cofactors |
1. Pyrophosphate (B1, thiamine; TPP)
2. FAD (B2, riboflavin) 3. NAD (B3, niacin) 4. CoA (B5, pantothenate) 5. Lipoic acid |
|
Pyruvate dehydrogenase complex
is similar to |
α-ketoglutarate
dehydrogenase complex (same cofactors, similar substrate and action). |
|
α-ketoglutarate dehydrogenase complex
is similar to |
Pyruvate dehydrogenase complex
(same cofactors, similar substrate and action). |
|
Arsenic
mech and clinical findings |
Arsenic inhibits lipoic acid (Pyruvate dehydrogenase complex cofactor):
Vomiting, Rice water stools Garlic breath |
|
Vomiting, Rice water stools
Garlic breath |
Arsenic
|
|
Pyruvate dehydrogenase complex
reaction |
Reaction: pyruvate + NAD+ + CoA → acetyl-CoA + CO2 + NADH.
|
|
Pyruvate dehydrogenase complex
activated by |
Activated by exercise:
↑ NAD+/NADH ratio ↑ ADP ↑ Ca2+ |
|
the only purely ketogenic amino
acids. |
Lysine and Leucine––
|
|
Pyruvate dehydrogenase deficiency
mech |
Causes backup of substrate (pyruvate and alanine),
resulting in lactic acidosis. Can be congenital or acquired (as in alcoholics due to B1 deficiency). |
|
Pyruvate dehydrogenase deficiency
findings |
neurologic defects.
|
|
Pyruvate dehydrogenase deficiency
Tx |
↑ intake of ketogenic nutrients (e.g., high fat content or ↑ lysine and leucine).
|
|
# are needed to generate glucose from pyruvate.
|
6 ATP equivalents
|
|
Pyruvate metabolism
Alanine |
carries amino groups
to the liver from muscle. |
|
Pyruvate metabolism
Oxaloacetate |
can replenish
TCA cycle or be used in gluconeogenesis. |
|
Cori cycle
mech and why |
Transfers excess reducing
equivalents from RBCs and muscle to liver, allowing muscle to function anaerobically (net 2 ATP). Shifts metabolic burden to the liver. |
|
Transfers excess reducing
equivalents from RBCs and muscle to liver, allowing muscle to function anaerobically (net 2 ATP). Shifts metabolic burden to the liver. |
Cori cycle
|
|
TCA cycle
what is produced/per what |
Produces 3 NADH, 1 FADH2,
2 CO2, 1 GTP per acetyl- CoA = 12 ATP/acetyl-CoA (2× everything per glucose) |
|
TCA cycle
complex and features |
α-ketoglutarate dehydrogenase
complex requires same cofactors as the pyruvate dehydrogenase complex (B1, B2, B3, B5, lipoic acid). |
|
TCA cycle
order of things from Acetyl-CoA |
Can IKeep Selling Sex
For Money, Officer? Citrate Isocitrate α-ketoglutarate Succinyl-CoA Succinate Fumarate Malate Oxalo-acetate |
|
Electron transport
chain yields from input's |
1 NADH → 3 ATP;
1 FADH2 → 2 ATP. |
|
Oxidative phosphorylation poisons
↑ permeability of membrane, causing a ↓ proton gradient and ↑ O2 consumption. ATP synthesis stops, but electron transport continues. |
Uncoupling agents
(UCP, 2,4-DNP, aspirin) |
|
Oxidative phosphorylation poisons
UCP, 2,4-DNP, aspirin |
Uncoupling agents
↑ permeability of membrane, causing a ↓ proton gradient and ↑ O2 consumption. ATP synthesis stops, but electron transport continues. |
|
Oxidative phosphorylation poisons
Rotenone, CN–, antimycin A, CO |
Electron transport
inhibitors |
|
Oxidative phosphorylation poisons
Directly inhibit electron transport, causing a ↓ proton gradient and block of ATP synthesis. |
Electron transport
inhibitors -Rotenone, -cyanide, -antimycin A, -CO |
|
Oxidative phosphorylation poisons
Directly inhibit mitochondrial ATPase, causing an ↑ proton gradient, but no ATP is produced because electron transport stops. |
ATPase inhibitors
Oligomycin |
|
Oxidative phosphorylation poisons
Oligomycin |
ATPase inhibitors
Directly inhibit mitochondrial ATPase, causing an ↑ proton gradient, but no ATP is produced because electron transport stops. |
|
Gluconeogenesis, irreversible enzymes (where, what, regulation/requirements)
Pyruvate carboxylase |
In mitochondria.
Pyruvate → oxaloacetate. Requires biotin, ATP. Activated by acetyl-CoA. |
|
Gluconeogenesis, irreversible enzymes
In mitochondria. Pyruvate → oxaloacetate. Requires biotin, ATP. Activated by acetyl-CoA. |
Pyruvate carboxylase
|
|
Gluconeogenesis, irreversible enzymes (where, what, requirements)
PEP carboxykinase |
In cytosol.
Oxaloacetate → phosphoenolpyruvate. Requires GTP. |
|
Gluconeogenesis, irreversible enzymes
In cytosol. Oxaloacetate → phosphoenolpyruvate. Requires GTP. |
PEP carboxykinase
|
|
Gluconeogenesis, irreversible enzymes (where, what, regulation/requirements)
Fructose-1,6- bisphosphatase |
In cytosol.
Fructose-1,6-bisphosphate → fructose-6-P. |
|
Gluconeogenesis, irreversible enzymes
In cytosol. Fructose-1,6-bisphosphate → fructose-6-P. |
Fructose-1,6-
bisphosphatase |
|
Gluconeogenesis, irreversible enzymes (where, what, regulation/requirements)
Glucose-6- phosphatase |
In ER. Glucose-6-P → glucose.
|
|
Gluconeogenesis, irreversible enzymes
name them |
Pathway Produces Fresh Glucose.
-Pyruvate carboxylase -PEP carboxykinase -Fructose-1,6-bisphosphatase -Glucose-6- phosphatase |
|
Gluconeogenesis, irreversible enzymes
In ER. Glucose-6-P → glucose. |
Glucose-6-
phosphatase |
|
Gluconeogenesis, irreversible enzymes
locations in body |
Above enzymes found only in liver, kidney, intestinal epithelium. Muscle cannot
participate in gluconeogenesis. |
|
Deficiency of the key gluconeogenic enzymes causes
|
hypoglycemia.
|
|
Pentose phosphate pathway (HMP
shunt) why |
Produces NADPH, which is required for fatty acid and steroid biosynthesis and for
glutathione reduction inside RBCs. and nucleotide synthesis |
|
Pentose phosphate pathway (HMP
shunt) where (in the the cell and body |
All reactions of this pathway occur in the cytoplasm.
Sites: lactating mammary glands, liver, adrenal cortex––all sites of fatty acid or steroid synthesis. |
|
Pentose phosphate pathway (HMP
shunt) wrt ATP |
No ATP is used or produced.
|
|
Pentose phosphate pathway
aka |
HMP shunt
|
|
HMP shunt aka
|
Pentose phosphate pathway
|
|
Pentose phosphate pathway (HMP
shunt) Oxidative reaction features, key enzymes, and products (with reasons) |
(irreversible)
Glucose-6-phosphate dehydrogenase NADPH |
|
Pentose phosphate pathway (HMP
shunt) Nonoxidative reaction features, key enzymes, and products (with reasons) |
(reversible)
Transketolases (require thiamine) Ribose-5-phosphate (Ribose-5-phosphate (for nucleotide synthesis), G3P, F6P (glycolytic intermediates) |
|
Glucose-6-phosphate
dehydrogenase deficiency who |
G6PD deficiency is more
prevalent among blacks. |
|
Glucose-6-phosphate
dehydrogenase deficiency histo |
Heinz bodies––altered
Hemoglobin precipitates within RBCs. |
|
Glucose-6-phosphate
dehydrogenase deficiency clinical findings |
hemolytic anemia due to poor
RBC defense against oxidizing agents (fava beans, sulfonamides, primaquine) and antituberculosis drugs. |
|
hemolytic anemia due to poor
RBC defense against oxidizing agents (fava beans, sulfonamides, primaquine) and antituberculosis drugs. |
Glucose-6-phosphate
dehydrogenase deficiency |
|
Fructose intolerance
mech |
deficiency of aldolase B (recessive). fructose-1-phosphate accumulates, causing a ↓ in available phosphate, which results in inhibition of glycogenolysis
and gluconeogenesis. |
|
Fructose intolerance
findings |
hypoglycemia, jaundice, cirrhosis, vomiting.
|
|
Fructose intolerance
Tx |
must ↓ intake of both fructose and sucrose (glucose + fructose).
|
|
Essential fructosuria
|
Involves a defect in fructokinase and is a benign, asymptomatic condition.
Symptoms: fructose appears in blood and urine. |
|
Involves a defect in fructokinase and is a benign, asymptomatic condition.
fructose appears in blood and urine. |
Essential fructosuria
|
|
Galactosemia
mech |
Absence of galactose-1-phosphate uridyltransferase. Autosomal recessive. Damage is
caused by accumulation of toxic substances (including galactitol) rather than absence of an essential compound. |
|
Galactosemia
clinical findings |
cataracts, hepatosplenomegaly, mental retardation.
|
|
Galactosemia
Tx |
exclude galactose and lactose (galactose + glucose) from diet.
|
|
Amino acids
Ketogenic: |
Leu, Lys
|
|
Amino acids
Glucogenic/ketogenic |
Ile, Phe, Trp
|
|
Amino acids
Glucogenic |
Met, Thr, Val, Arg, His
|
|
Amino acids
Essential |
PVT. TIM HALL always argues, never tires":
Phe- Val- Thr- Trp- Ile- Met- His- Arg- Lue- Lys |
|
Amino acids
Acidic |
Asp and Glu
|
|
Amino acids
Basic (and relative strengths) |
Arg, Lys, and His.
Arg is most basic. His has no charge at body pH. |
|
Hyperammonemia
who |
Can be acquired (e.g., liver disease) or hereditary
(e.g., ornithine transcarbamoylase deficiency). |
|
Hyperammonemia
mech |
Excess NH4 depletes α-ketoglutarate, leading to
inhibition of TCA cycle. |
|
Hyperammonemia
Tx |
arginine.
|
|
Hyperammonemia
clinical findings |
Ammonia intoxication: tremor,
slurring of speech, somnolence, vomiting, cerebral edema, blurring of vision. |
|
Urea cycle
what and why |
Degrades amino acids into amino groups. Accounts
for 90% of nitrogen in urine. |
|
Urea cycle
order |
Ordinarily, Careless Crappers
Are Also Frivolous About Urination. Ornithine + Carbamoyl phosphate go to Citruline which combines with Aspartate going to Argininosuccinate releasing fumarate and arginine (which combines with water to release Urea and ornithine) back to top |
|
Amino acid derivatives
Phenylalanine |
from first to last
Tyrosine ^(Thyroxine) to Dopamine to Dopa ^(Melanin) to NE to Epi |
|
Amino acid derivatives
Tryptophan |
-Niacin ^ (NAD+/NADP+)
or -Melatonin or -Serotonin |
|
Amino acid derivatives
Histidine |
Histamine
|
|
Amino acid derivatives
Glycine |
to Porphyrin to Heme
|
|
Amino acid derivatives
Arginine |
Urea
or Nitric oxide or Creatine |
|
Amino acid derivatives
Glutamate |
GABA (glutamate decarboxylase—requires B6)
|
|
What is the original amino acid for
NE Thyroxine Tyrosine Dopamine Dopa Epi Melanin |
Phenylalanine
|
|
What is the original amino acid for
Niacin NAD+/NADP+ Melatonin Serotonin |
Tryptophan
|
|
What is the original amino acid for
Histamine |
Histidine
|
|
What is the original amino acid for
Porphyrin Heme |
Glycine
|
|
What is the original amino acid for
Urea Nitric oxide Creatine |
Arginine
|
|
What is the original amino acid for
GABA (glutamate decarboxylase—requires B6) |
Glutamate
|
|
Normally, phenylalanine is converted into
|
tyrosine
|
|
Phenylketones
name the three |
––phenylacetate,
phenyllactate, and phenylpyruvate. |
|
Phenylketonuria
mech |
there is ↓ phenylalanine
hydroxylase or ↓ tetrahydrobiopterin cofactor. Tyrosine becomes essential and phenylalanine builds up, leading to excess phenylketones in urine. |
|
Phenylketonuria
clinical findings |
mental retardation, growth retardation, fair skin, eczema, musty body odor.
|
|
Phenylketonuria
Tx |
Treatment: ↓ ↓ phenylalanine (contained in
aspartame, e.g., NutraSweet) and ↑ ↑ tyrosine in diet. |
|
Alkaptonuria
aka |
ochronosis
|
|
ochronosis
aka |
Alkaptonuria
|
|
Alkaptonuria
(ochronosis) mech and findings |
Congenital deficiency of homogentisic acid oxidase in the degradative pathway of
tyrosine. Resulting alkapton bodies cause urine to turn black on standing. Also, the connective tissue is dark. Benign disease. May have debilitating arthralgias. |
|
Albinism
causes |
Congenital deficiency of either of the following:
1. Tyrosinase (inability to synthesize melanin from tyrosine) 2. Defective tyrosine transporters (↓ amounts of tyrosine and thus melanin) -Can result from a lack of migration of neural crest cells. |
|
Albinism
wrt inheritance |
AR - Variable inheritance due to
locus heterogeneity. |
|
Albinism
wrt risk |
Lack of melanin results in an
↑ risk of skin cancer. |
|
Homocystinuria
3 forms mech and Tx |
1. Cystathionine synthase deficiency (treatment:
↓ Met and ↑ Cys in diet) 2. ↓ affinity of cystathionine synthase for pyridoxal phosphate (treatment: ↑↑ vitamin B6 in diet) 3. Methionine synthase deficiency |
|
Homocystinuria
general mech |
Results in excess homocysteine
in the urine. Cysteine becomes essential. |
|
Homocystinuria
findings |
Can cause mental retardation,
osteoporosis, tall stature, kyphosis, lens subluxation (downward and inward), and atherosclerosis (stroke and MI). |
|
Cystinuria
mech |
Common (1:7000) inherited defect of renal tubular
amino acid transporter for Cystine, Ornithine, Lysine, and Arginine in kidneys. COLA |
|
Cystinuria clinical findings and Tx
|
Excess cystine in urine can lead to the precipitation
of cystine kidney stones. Treat with acetazolamide to alkalinize the urine. |
|
Maple syrup urine disease
mech |
Blocked degradation of branched amino acids
(Ile, Val, Leu) "I Love Vermont maple syrup" due to ↓α-ketoacid dehydrogenase. Causes ↑α-ketoacids in the blood, especially Leu. |
|
Maple syrup urine disease
clinical findings |
Urine smells like maple syrup.
Causes severe CNS defects, mental retardation, and death. |
|
Lesch-Nyhan syndrome
mech |
Purine salvage problem owing to absence of HGPRTase. Results in excess uric acid production.
|
|
Lesch-Nyhan syndrome
findings |
Findings: retardation, self-mutilation, aggression,
hyperuricemia, gout, and choreoathetosis. |
|
retardation, self-mutilation, aggression, hyperuricemia, gout, and choreoathetosis.
|
Lesch-Nyhan syndrome
|
|
Adenosine deaminase deficiency
mech |
Excess ATP and dATP imbalances nucleotide pool via feedback inhibition of ribonucleotide reductase. This prevents DNA synthesis and thus ↓ lymphocyte count.
|
|
1st disease to be treated by experimental
human gene therapy. |
Adenosine deaminase deficiency
|
|
Adenosine deaminase deficiency
complications |
SCID––severe combined
(T and B) immunodeficiency |
|
Liver: fed state vs.
fasting state what is released in fed state |
just VLDL
|
|
Liver: fed state vs.
fasting state what is released in fasting state |
Glucose
and Ketone bodies |
|
Liver: fed state vs.
fasting state mnemonic |
In the PHasting state,
PHosphorylate. |
|
what cells don't need insulin to uptake glucose
|
BRICK L:
Brain RBCs Intestine Cornea Kidney Liver |
|
Where are different GLUT's
and different activities |
-GLUT1: RBCs, brain
-GLUT2 (bidirectional): β islet cells, liver, kidney -GLUT4 (insulin responsive): adipose tissue, skeletal muscle |
|
5 Anabolic effects of insulin:
|
1. ↑ glucose transport
2. ↑ glycogen synthesis and storage 3. ↑ triglyceride synthesis and storage 4. ↑ Na retention (kidneys) 5. ↑ protein synthesis (muscles) |
|
Serum C-peptide is not present with
|
exogenous insulin intake.
|
|
???? inhibits glucagon
release by α cells of pancreas. |
insulin
|
|
Glycogen synthase
regulation in liver and muscle |
Liver:
⊕Insulin and/or Glucose -Glucagon and or Epinephrine Muscle: ⊕Insulin -Epinephrine |
|
Glycogen phosphorylase
regulation in liver and muscle |
Liver
⊕Epinephrine and or Glucagon -Insulin Muscle: ⊕AMP and/or epinephrine -ATP and/or Insulin |
|
Required for adipose
and skeletal muscle uptake of glucose. |
Insulin
|
|
Glycogen storage diseases
names of the main ones |
"Very Poor Carbohydrate
Metabolism" Von Gierke’s disease (Type I) Pompe’s disease(Type II) Cori’s disease(Type III) McArdle’s disease (Type V) |
|
Glycogen storage diseases
#'s and features |
12 types, all resulting in abnormal glycogen metabolism and an accumulation of glycogen within cells.
|
|
Von Gierke’s disease
Findings, Deficient enzyme and comments |
Severe fasting hypoglycemia, ↑↑ glycogen in liver, ↑ blood
lactate, hepatomegaly. Glucose-6-phosphate. -The liver becomes a muscle. (Think about it.) |
|
Pompe’s disease
Findings, Deficient enzyme and comments |
Cardiomegaly and systemic
findings leading to early death. Lysosomal α-1,4- glucosidase (acid maltase). Pompe’s trashes the Pump (heart, liver, and muscle). |
|
Cori’s disease
Findings, Deficient enzyme and comments |
Milder form of Type I with normal
blood lactate levels. Debranching enzyme α-1,6-glucosidase. |
|
McArdle’s disease
Findings, Deficient enzyme and comments |
↑glycogen in muscle, but cannot break it down, leading to painful muscle cramps, myoglobinuria with strenuous exercise.
Skeletal muscle glycogen phosphorylase. |
|
↑glycogen in muscle, but cannot break it down, leading to painful muscle cramps, myoglobinuria with strenuous exercise.
|
McArdle’s disease
|
|
Severe fasting hypoglycemia, ↑↑
glycogen in liver, ↑ blood lactate, hepatomegaly. |
Von Gierke’s disease
|
|
Cardiomegaly and systemic
findings leading to early death. |
Pompe’s disease
|
|
Inheritance of Lysosomal storage diseases
|
Fabry’s disease and Hunter’s syndrome are XR
the rest are AR |
|
Fabry’s disease
Findings /Deficient enzyme /Accumulated substrate |
Peripheral neuropathy of
hands/feet, angiokeratomas, cardiovascular/renal disease α-galactosidase A Ceramide trihexoside |
|
Gaucher’s disease
Findings /Deficient enzyme /Accumulated substrate |
Hepatosplenomegaly,
aseptic necrosis of femur, bone crises, Gaucher’s cells (macrophages) β-glucocerebrosidase Glucocerebroside |
|
Niemann-Pick
disease Findings /Deficient enzyme /Accumulated substrate |
"No man picks (Niemann-Pick)
his nose with his sphinger (sphingomyelinase)." Progressive neurodegeneration, hepatosplenomegaly, cherry- red spot (on macula) Sphingomyelinase Sphingomyelin |
|
Tay-Sachs disease
Findings /Deficient enzyme /Accumulated substrate |
Progressive neurodegeneration,
developmental delay, cherry-red spot, lysozymes with onion skin ' Tay-SaX (Tay-Sachs) lacks heXosaminidase." Hexosaminidase A GM2 ganglioside |
|
Krabbe’s disease
Findings /Deficient enzyme /Accumulated substrate |
Peripheral neuropathy,
developmental delay, optic atrophy β-galactosidase Galactocerebroside |
|
Metachromatic
leukodystrophy Findings /Deficient enzyme /Accumulated substrate |
Central and peripheral
demyelination with ataxia, dementia Arylsulfatase A Cerebroside sulfate |
|
Hurler’s syndrome
Findings /Deficient enzyme /Accumulated substrate |
Developmental delay,
gargoylism, airway obstruction, corneal clouding, hepatosplenomegaly α-L-iduronidase Heparan sulfate, dermatan sulfate |
|
Hunter’s syndrome
Findings /Deficient enzyme /Accumulated substrate |
Mild Hurler’s + aggressive
behavior, no corneal clouding Iduronate sulfatase Heparan sulfate, dermatan sulfate |
|
Lysosomal storage diseases
names and general classes |
Sphingoliposes:
Fabry’s disease - Gaucher’s disease - Niemann-Pick - Tay-Sachs disease - Krabbe’s disease - Metachromatic leukodystrophy Mucopolysaccharidoses: Hurler’s syndrome -Hunter’s syndrome |
|
Lysosomal storage diseases
most common |
Gaucher’s disease
|
|
Hepatosplenomegaly,
aseptic necrosis of femur, bone crises, Gaucher’s cells (macrophages) |
Gaucher’s disease
|
|
Progressive neurodegeneration,
hepatosplenomegaly, cherry- red spot (on macula) |
Niemann-Pick
disease Tay-Sachs disease |
|
Peripheral neuropathy of
hands/feet, angiokeratomas, cardiovascular/renal disease |
Fabry’s disease
|
|
inability to utilize LCFAs
and toxic accumulation. |
Carnitine deficiency:
|
|
Ketone bodies
where/how/why produced |
In liver: fatty acid and amino acids → HMG-CoA → acetoacetate + β-hydroxybutyrate (to be used in muscle and brain Ketone bodies are metabolized by the brain to 2 molecules of
acetyl-CoA.) |
|
Ketone bodies
when |
prolonged starvation and diabetic ketoacidosis
|
|
Cholesterol synthesis
rate limiting step and mech and wrt esterificatoin |
Rate-limiting step is catalyzed by HMG-CoA
reductase, which converts HMG-CoA to mevalonate. 2⁄3 of plasma cholesterol is esterified by lecithin-cholesterol acyltransferase (LCAT). |
|
Lovastatin inhibits
|
HMG-
CoA reductase. |
|
what inhibits HMG-
CoA reductase. |
statins
|
|
Essential fatty acids
and why |
Linoeic and linolenic acids.
Arachidonic acid, if linoleic acid is absent. Eicosanoids are dependent on essential fatty acids. |
|
Lipases (function/which one)
degradation of dietary TG in small intestine. |
Pancreatic lipase
|
|
Lipases (function/which one)
Pancreatic lipase |
degradation of dietary TG in small intestine.
|
|
Lipases (function/which one)
Lipoprotein lipase |
degradation of TG circulating in chylomicrons and VLDLs.
|
|
Lipases (function/which one)
degradation of TG circulating in chylomicrons and VLDLs. |
Lipoprotein lipase
|
|
Lipases (function/which one)
Hepatic TG lipase |
degradation of TG remaining in IDL.
|
|
Lipases (function/which one)
degradation of TG remaining in IDL. |
Hepatic TG lipase
|
|
Lipases (function/which one)
Hormone-sensitive lipase |
degradation of TG stored in adipocytes.
|
|
Lipases (function/which one)
degradation of TG stored in adipocytes. |
Hormone-sensitive lipase
|
|
fat enzymes (function/which one)
Lecithin-cholesterol acyltransferase (LCAT) |
catalyzes esterification of cholesterol.
|
|
fat enzymes (function/which one)
catalyzes esterification of cholesterol. |
Lecithin-cholesterol acyltransferase (LCAT)
|
|
fat enzymes (function/which one)
Cholesterol ester transfer protein (CETP) |
mediates transfer of cholesterol esters to other lipoprotein particles.
|
|
fat enzymes (function/which one)
mediates transfer of cholesterol esters to other lipoprotein particles. |
Cholesterol ester transfer protein (CETP)
|
|
Major apolipoproteins
function of A-I |
Activates LCAT.
|
|
Major apolipoproteins
Activates LCAT. |
A-I
|
|
Major apolipoproteins
function of B-100 |
Binds to LDL receptor, mediates VLDL secretion.
|
|
Major apolipoproteins
Binds to LDL receptor, mediates VLDL secretion. |
B-100
|
|
Major apolipoproteins
function of C-II |
Cofactor for lipoprotein lipase.
|
|
Major apolipoproteins
Cofactor for lipoprotein lipase. |
C-II
|
|
Major apolipoproteins
function of B-48 |
Mediates chylomicron secretion.
|
|
Major apolipoproteins
Mediates chylomicron secretion. |
B-48
|
|
Major apolipoproteins
Mediates Extra (remnant) uptake. |
E
|
|
Major apolipoproteins
function of E |
Mediates Extra (remnant) uptake.
|
|
Which lipoproteins are on
IDL |
B-100
E |
|
Which lipoproteins are on
LDL |
B-100
|
|
Which lipoproteins are on
VLDL |
C-II
B-100 E |
|
Which lipoproteins are on
Chylomicron remnant |
B-48
E |
|
Which lipoproteins are on
Chylomicron |
A
B-48 C-II E |
|
Lipoprotein
compositions |
Lipoproteins are composed of varying proportions of cholesterol, triglycerides,
and phospholipids. |
|
carry most cholestero
|
LDL and HDL
|
|
Function and route
Chylomicron |
Delivers dietary triglycerides to peripheral tissues and
dietary cholesterol to liver. Secreted by intestinal epithelial cells. |
|
Function and route
VLDL |
Delivers hepatic triglycerides to peripheral tissues
Secreted by liver. |
|
Function and route
IDL |
Formed in the degradation of VLDL. Delivers triglycerides and cholesterol to liver, where they
are degraded to LDL. |
|
Function and route
LDL |
Delivers hepatic cholesterol to peripheral tissues.
Formed by lipoprotein lipase modification of VLDL in the peripheral tissue. Taken up by targe cells via receptor-mediated endocytosis. |
|
Function and route
HDL |
Mediates centripetal transport of cholesterol (reverse cholesterol transport, from periphery to liver). Acts as a repository for apoC and apoE (which are
needed for chylomicron and VLDL metabolism). Secreted from both liver and intestine. |
|
Familial dyslipidemias
Type I -aka -What is increased -elevated blood levels -pathophys |
I––hyperchylomicronemia
Chylomicrons TG, cholesterol Lipoprotein lipase deficiency or altered apolipoprotein C-II |
|
Familial dyslipidemias
Type IIa -aka -What is increased -elevated blood levels -pathophys |
IIa––hypercholesterolemia
LDL Cholesterol ↓ LDL receptors |
|
Familial dyslipidemias
Type IV -aka -What is increased -elevated blood levels -pathophys |
IV––hypertriglyceridemia
VLDL TG Hepatic overproduction of VLDL |
|
Underproduction of heme causes ?
Accumulation of intermediates causes ? |
microcytic hypochromic anemia.
porphyrias. |
|
Porphyrias
name them |
Lead poisoning
Acute intermittent porphyria Porphyria cutanea tarda |
|
Porphyrias
symptyoms |
Symptoms = 5 P’s:
Painful abdomen, Pink urine, Polyneuropathy, Psychological disturbances, Precipitated by drugs |
|
Affected enzyme and
Accumulated substrate in urine Lead poisoning |
Ferrochelatase and ALA dehydrase
Coproporhyrin and ALA |
|
Affected enzyme and
Accumulated substrate in urine Acute intermittent porphyria |
porphobilinogen deaminase
Porphobilinogen and δ-ALA |
|
Affected enzyme and
Accumulated substrate in urine Porphyria cutanea tarda |
Uroporphyrinogen decarboxylase
Uroporphyrin (tea-colored) |
|
Heme catabolism
scavanve mech |
Heme is scavenged from RBCs and Fe2+ is reused. Heme →biliverdin →bilirubin
|
|
what makes bruises blue/green
|
biliverdin
|
|
Heme catabolism
wrt newborns |
jaundiced newborns are put under UV light which converts bilirubin into urine- solubile products
|
|
Hemoglobin
formations and implications |
1. T (taut) form has low affinity for O2.
2. R (relaxed) form has high affinity for O2 (300×). |
|
Hemoglobin
wrt allosteric |
Hemoglobin exhibits positive
cooperativity and negative allostery (accounts for the sigmoid-shaped O2 dissociation curve for hemoglobin), unlike myoglobin. |
|
how can fetal Hb take O2 from Hb
|
Fetal hemoglobin (2α and 2γ
subunits) has lower affinity for 2,3-BPG than adult hemoglobin (HbA) and thus has higher affinity for O2. |
|
↑ Cl−, H+, CO2, 2,3-BPG, and temperature shifts dissociation curve to right, leading to ↑ O2 unloading)
HOW? |
favor T form over R form promoting O2 unloading (negative allosteric regulation).
|
|
CO2 transport in
blood by Hb (where) |
CO2 (primarily as bicarbonate) binds to amino acids in globin chain at N terminus, but not
to heme. |
|
cyanide poisoning
Tx and mech |
Administer nitrites in cyanide
poisoning to oxidize hemoglobin to methemoglobin. |
|
Methemoglobin
|
Oxidized form of hemoglobin (ferric, Fe3+) that does not bind O2 as readily, but has ↑ affinity for CN–.
|
|
Iron in hemoglobin is normally
|
in a reduced
state (ferrous, Fe2+). |
|
Carboxyhemoglobin
|
Form of hemoglobin bound to CO in place of O2.
|
|
Form of hemoglobin bound to CO in place of O2.
|
Carboxyhemoglobin
|
|
Oxidized form of hemoglobin (ferric, Fe3+) that does not bind O2 as readily, but has ↑ affinity for CN–.
|
Methemoglobin
|
|
Methemoglobin
Tx |
Treat toxic levels of
METHemoglobin with METHylene blue. |
|
CO has a ?????? affinity
than O2 for hemoglobin. |
200× greater
|
|
Polymerase chain
reaction (PCR) steps |
1. DNA is denatured by heating to generate 2 separate strands
2. During cooling, excess premade DNA primers anneal to a specific sequence on eac strand to be amplified 3. Heat-stable DNA polymerase replicates the DNA sequence following each primer |
|
different direction blots
|
SNoW DRoP:
Southern = DNA Northern = RNA Western = Protein |
|
A rapid immunologic technique testing for antigen-antibody reactivity.
|
Enzyme-linked immunosorbent assay (ELISA)
|
|
Enzyme-linked immunosorbentassay (ELISA)
why |
to determinewhether a particular
antibody (e.g., anti-HIV) is present in a patient’s blood ample. Both the sensitivity |
|
Fluorescence in situ hybridization (FISH)
|
Fluorescent probe binds to specific gene site of interest.
Specific localization of genes and direct visualization of anomalies at molecular level. |
|
Genetic terms
Variable expression |
Nature and severity of the phenotype varies from 1 individual to another.
|
|
Genetic terms
Nature and severity of the phenotype varies from 1 individual to another. |
Variable expression
|
|
Genetic terms
Incomplete penetrance |
Not all individuals with a mutant genotype show the mutant phenotype.
|
|
Genetic terms
Not all individuals with a mutant genotype show the mutant phenotype. |
Incomplete penetrance
|
|
Genetic terms
Pleiotropy |
1 gene has > 1 effect on an individual’s phenotype.
|
|
Genetic terms
1 gene has > 1 effect on an individual’s phenotype. |
Pleiotropy
|
|
Genetic terms
Imprinting |
Differences in phenotype depend on whether the mutation is of maternal or paternal
origin (e.g., AngelMan’s syndrome [Maternal], Prader-Willi syndrome [Paternal]). |
|
Genetic terms
Differences in phenotype depend on whether the mutation is of maternal or paternal origin |
Imprinting
|
|
Genetic terms
Anticipation |
Severity of disease worsens or age of onset of disease is earlier in succeeding generations
(e.g., Huntington’s disease). |
|
Genetic terms
Severity of disease worsens or age of onset of disease is earlier in succeeding generations |
Anticipation
|
|
Genetic terms
Loss of heterozygosity |
If a patient inherits or develops a mutation in a tumor suppressor gene, the complementary
allele must be deleted/mutated before cancer develops. This is not true of oncogenes. |
|
Genetic terms
If a patient inherits or develops a mutation in a tumor suppressor gene, the complementary allele must be deleted/mutated before cancer develops. This is not true of oncogenes. |
Loss of heterozygosity
|
|
Genetic terms
Dominant negative mutation |
Exerts a dominant effect. A heterozygote produces a nonfunctional altered protein that also prevents the normal gene product from functioning.
|
|
Genetic terms
Exerts a dominant effect. A heterozygote produces a nonfunctional altered protein that also prevents the normal gene product from functioning. |
Dominant negative mutation
|
|
Genetic terms
Linkage disequilibrium |
Tendency for certain alleles at 2 linked loci to occur together more often than
expected by chance. Measured in a population, not in a family, and often varies in different populations. |
|
Genetic terms
Tendency for certain alleles at 2 linked loci to occur together more often than expected by chance. Measured in a population, not in a family, and often varies in different populations. |
Linkage disequilibrium
|
|
Genetic terms
Mosaicism |
Occurs when cells in the body have different genetic makeup (e.g., lyonization––
random X inactivation in females). |
|
Genetic terms
Occurs when cells in the body have different genetic makeup |
Mosaicism
|
|
Genetic terms
Locus heterogeneity |
Mutations at different loci can produce the same phenotype (e.g., albinism).
|
|
Genetic terms
Mutations at different loci can produce the same phenotype |
Locus heterogeneity
|
|
Hardy-Weinberg law assumes:
|
1. no mutation occurring at the locus
2. There is no selection for any of the genotypes at the locus 3. random mating 4. no migration being considered |
|
Imprinting
describe the main example |
Prader-Willi ( Deletion of normally active paternal allele)
Angelman’s syndrome (Deletion of normally active maternal allele) |
|
Prader-Willi
findings |
Mental retardation, obesity,
hypogonadism, hypotonia. |
|
Angelman’s syndrome
findings |
Mental retardation, seizures,
ataxia, inappropriate laughter (happy puppet). |
|
Mental retardation, seizures,
ataxia, inappropriate laughter (happy puppet). |
Angelman’s syndrome
|
|
Mental retardation, obesity,
hypogonadism, hypotonia. |
Prader-Willi
|
|
Mitochondrial inheritance
diseases |
Leber’s hereditary optic
neuropathy; mitochondrial myopathies. |
|
Mitochondrial inheritance
mech |
Transmitted only through mother. All offspring of
affected females may show signs of disease. |
|
AR/AD/XR/XD
Adult polycystic kidney disease |
AD
|
|
AR/AD/XR/XD
Familial hypercholesterolemia |
AD
|
|
AR/AD/XR/XD
Marfan’s syndrome |
AD
|
|
AR/AD/XR/XD
von Recklinghausen’s disease |
AD
|
|
AR/AD/XR/XD
Neurofibromatosis type 1 |
AD
|
|
AR/AD/XR/XD
Neurofibromatosis type 2 |
AD
|
|
AR/AD/XR/XD
Tuberous sclerosis |
AD
|
|
AR/AD/XR/XD
Von Hippel–Lindau disease |
AD
|
|
AR/AD/XR/XD
Huntington’s disease |
AD
|
|
AR/AD/XR/XD
Familial adenomatous polyposis |
AD
|
|
AR/AD/XR/XD
Hereditary spherocytosis |
AD
|
|
AR/AD/XR/XD
Achondroplasia |
AD
|
|
AR/AD/XR/XD
Cystic fibrosis |
AR
|
|
AR/AD/XR/XD
albinism |
AR
|
|
AR/AD/XR/XD
α1-antitrypsin deficiency |
AR
|
|
AR/AD/XR/XD
phenylketonuria |
AR
|
|
AR/AD/XR/XD
thalassemias |
AR
|
|
AR/AD/XR/XD
sickle cell anemias |
AR
|
|
AR/AD/XR/XD
glycogen storage diseases |
AR
|
|
AR/AD/XR/XD
mucopolysaccharidoses |
AR
(except Hunter’s), |
|
AR/AD/XR/XD
sphingolipidoses |
AR
(except Fabry’s) |
|
AR/AD/XR/XD
infant polycystic kidney disease |
AR
|
|
AR/AD/XR/XD
hemochromatosis |
AR
|
|
AR/AD/XR/XD
Bruton's agammaglobulinemia |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Wiskott-Aldrich syndrome |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Fragile X |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
G6PD deficiency |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Ocular albinism |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Lesch-Nyhan syndrome |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Duchenne's muscular dystrophy |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Hemophilia A and B |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Fabry's disease |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
AR/AD/XR/XD
Hunter's syndrome |
XR
Be Wise, Fool's GOLD Heeds False Hope. |
|
name the XR disorders
|
Be Wise, Fool's GOLD Heeds
False Hope Bruton's agammaglobulinemia, Wiskott-Aldrich syndrome, Fragile X, G6PD deficiency, Ocular albinism, Lesch-Nyhan syndrome, Duchenne muscular dystrophy, Hemophilia A and B, Fabry's disease, Hunter's syndrome. |
|
Adult polycystic kidney
disease presentation |
Always bilateral, massive enlargement of kidneys due to multiple large cysts. Patients
present with pain, hematuria, hypertension, progressive renal failure. |
|
Adult polycystic kidney
disease specific genetics |
are due to mutation in APKD1 (chromosome 16)
|
|
Adult polycystic kidney
disease associations |
Associated with polycystic liver
disease, berry aneurysms, mitral valve prolapsediverticulosis |
|
Familial hypercholesterolemia
(hyperlipidemia type IIA) clinical findings |
severe atherosclerotic disease early in life, and tendon xanthomas (classically in the
Achilles tendon); MI may develop before age 20. |
|
Familial hypercholesterolemia
(hyperlipidemia type IIA) lab findings |
Elevated LDL owing to defective or absent LDL receptor. Heterozygotes (1:500) have cholesterol ≈ 300 mg/dL. Homozygotes (very rare) have cholesterol ≈ 700+ mg/dL,
|
|
Marfan’s syndrome
Skeletal abnormalities |
tall with long extremities (arachnodactyly), pectus
excavatum, hyperextensive joints, and long, tapering fingers and toes (see Image 109). |
|
Marfan’s syndrome
vascular findings |
Cardiovascular––cystic medial necrosis of aorta → aortic incompetence and
dissecting aortic aneurysms. Floppy mitral valve. |
|
Marfan’s syndrome
ocular findings |
Ocular––subluxation of lenses.
|
|
Neurofibromatosis type 1
aka |
von Recklinghausen’s disease
|
|
von Recklinghausen’s disease
aka |
Neurofibromatosis type 1
|
|
Neurofibromatosis
type 1 (von Recklinghausen’s disease) findings |
café-au-lait spots, neural tumors, Lisch nodules (pigmented iris hamartomas). Also marked by skeletal disorders (e.g., scoliosis), optic pathway
gliomas, pheochromocytoma, and ↑ tumor susceptibility. |
|
due to mutation in APKD1 (chromosome 16)
|
Adult polycystic kidney
disease |
|
café-au-lait spots, neural tumors, Lisch nodules (pigmented iris
hamartomas). Also marked by skeletal disorders (e.g., scoliosis), optic pathway gliomas, pheochromocytoma, and ↑ tumor susceptibility. |
Neurofibromatosis
type 1 (von Recklinghausen’s disease) |
|
what are Lisch nodules
|
pigmented iris hamartomas seen in Neurofibromatosis
type 1 |
|
Neurofibromatosis
type 1 (von Recklinghausen’s disease) specific genetics |
On long arm of chromosome17; 17 letters in von Recklinghausen or Neurofibromatosis
|
|
On long arm of chromosome17
|
Neurofibromatosis
17 letters in von Recklinghausen or Neurofibromatosis |
|
Neurofibromatosis type 2
clinical findings |
Bilateral acoustic neuroma, juvenile cataracts
|
|
Neurofibromatosis type 2
specific genetics |
NF2 gene on chromosome 22;
type 2 = 22. |
|
NF2 gene on chromosome 22;
|
Neurofibromatosis type 2
type 2 = 22 |
|
Tuberous sclerosis
findings |
Findings: facial lesions (adenoma sebaceum), hypopigmented “ash leaf spots” on skin,
cortical and retinal hamartomas, seizures, mental retardation, renal cysts, cardiac rhabdomyomas. Incomplete penetrance, variable presentation. |
|
facial lesions (adenoma sebaceum), hypopigmented “ash leaf spots” on skin, cortical and retinal hamartomas, seizures, mental retardation, renal cysts, cardiac rhabdomyomas.
|
Tuberous sclerosis
|
|
Von Hippel–Lindau
disease findings |
hemangioblastomas of retina/cerebellum/medulla; about half of affected
individuals develop multiple bilateral renal cell carcinomas and other tumors. |
|
hemangioblastomas of retina/cerebellum/medulla; about half of affected
individuals develop multiple bilateral renal cell carcinomas and other tumors. |
Von Hippel–Lindau
disease |
|
Associated with deletion of VHL gene (tumor suppressor) on chromosome 3 (3p).
|
Von Hippel–Lindau = 3 words for chromosome 3.
|
|
Von Hippel–Lindau
disease specific genetics |
Associated with deletion of VHL gene (tumor suppressor) on chromosome 3 (3p).
Von Hippel–Lindau = 3 words for chromosome 3. |
|
Huntington’s disease
clinical findings |
Findings: depression, progressive dementia, choreiform movements, Symptoms manifest in affected individuals between the ages of 20 and 50.
|
|
Huntington’s disease
lab/gross findings |
caudate atrophy and ↓ levels of GABA and ACh in the brain.
|
|
Huntington’s disease
specific genetics |
Gene located on chromosome 4; triplet repeat disorder. “Hunting 4 food.”
|
|
Gene located on chromosome 4; triplet repeat disorder
|
Huntington’s disease
“Hunting 4 food.” |
|
Familial adenomatous
polyposis specific genetics |
Colon becomes covered with adenomatous polyps after puberty. Progresses to colon
cancer unless resected. |
|
Familial adenomatous
polyposis findings |
Deletion on chromosome 5; 5 letters in “polyp.”
|
|
Deletion on chromosome 5
|
Familial adenomatous
polyposis 5 letters in “polyp.” |
|
Hereditary
spherocytosis findings |
Spheroid erythrocytes; hemolytic anemia; increased MCHC.
|
|
Hereditary
spherocytosis Tx |
Splenectomy is curative.
|
|
Achondroplasia
gene/mech |
Autosomal-dominant cell-signaling defect of fibroblast growth factor (FGF) receptor 3.
|
|
Achondroplasia
findings |
Results in dwarfism; short limbs, but head and trunk are normal size
|
|
Achondroplasia
associations |
Associated with advanced paternal age.
|
|
Cystic fibrosis
specific genetics |
defect in CFTR gene on
chromosome 7, commonly deletion of Phe 508. |
|
Cystic fibrosis
specific complication in males |
Infertility in males due to absent vas deferens.
|
|
Most common lethal genetic
disease of Caucasians. |
Cystic fibrosis
|
|
Treatment: N-acetylcysteine
to loosen mucous plugs. |
Cystic fibrosis
|
|
Cystic fibrosis
Tx |
N-acetylcysteine to loosen mucous plugs.
|
|
Cystic fibrosis
mech |
Defective Cl− channel →secretion of abnormally thick mucus that plugs lungs, pancreas, and liver → recurrent pulmonary infections
|
|
What does the normal CFTR channel do
|
CFTR channel secretes Cl– in lungs and GI tract and reabsorbs Cl– from sweat.
|
|
Cystic fibrosis
Dx |
↑ concentration
of Cl− ions in sweat test is diagnostic. |
|
Cystic fibrosis
clinical findings |
liver → recurrent pulmonary infections (Pseudomonas species and S. aureus), chronic bronchitis, bronchiectasis, pancreatic
insufficiency (malabsorption [Fat-soluble vitamin deficiencies (A, D, E, K] and steatorrhea), meconium ileus in newborns. Infertility in males due to absent vas deferens. Can present as failure to thrive in infancy. |
|
recurrent pulmonary infections (Pseudomonas species and S. aureus)
|
Cystic fibrosis
|
|
Duchenne’s Muscular dystrophy
specific genetics |
Frame-shift mutation → deletion of dystrophin gene
|
|
Duchenne’s Muscular dystrophy
mech |
Frame-shift mutation → deletion of dystrophin gene → accelerated muscle breakdown.
|
|
Duchenne’s Muscular dystrophy
clinical findigns |
gene → accelerated muscle breakdown. Onset
before 5 years of age. Weakness begins in pelvic girdle muscles and progresses superiorly. Pseudohypertrophy of calf muscles due to fibrofatty replacement of muscle; cardiac myopathy |
|
Mutated dystrophin gene is less severe than
Duchenne’s. |
Becker’s
|
|
Duchenne’s Muscular dystrophy
Dx |
Diagnose muscular dystrophies
by ↑ CPK and muscle biopsy. |
|
Fragile X syndrome
specific genetics |
X-linked defect affecting the methylation and expression of the FMR1 gene. Triplet repeat disorder (CGG)n that may show genetic anticipation (germlike
expansion in females). |
|
X-linked defect affecting the methylation and expression of the FMR1 gene.
|
Fragile X syndrome
|
|
The 2nd most common cause of genetic mental retardation
|
Fragile X syndrome
|
|
Fragile X syndrome
findings |
-mental retardation
-macro-orchidism (enlarged testes) -long face with a large jaw, -large everted ears, -autism. |
|
-mental retardation
-macro-orchidism (enlarged testes) -long face with a large jaw, -large everted ears, -autism. |
Fragile X syndrome
|
|
Trinucleotide repeat expansion diseases
name them |
Huntington’s disease, myotonic dystrophy, Friedreich’s ataxia, fragile X syndrome.
"Try (trinucleotide) hunting for my fried eggs (X)" |
|
Autosomal trisomies
name them |
Down syndrome
(trisomy 21), Edwards’ syndrome (trisomy 18) Patau’s syndrome (trisomy 13) |
|
Most common chromosomal disorder
|
Down syndrome
|
|
Most common cause of congenital mental retardation.
|
Down syndrome
|
|
Down syndrome
8 findings |
1. mental
retardation, 2. flat facial profile, 3. prominent epicanthal folds, 4. simian crease, 5. duodenal atresia, 6. congenital heart disease 7. Alzheimer’s disease in affected individuals > 35 years old, 8. ↑ risk of ALL. |
|
Down syndrome
what kind of heart defect |
heart disease
(most common malformation is septum primum–type ASD due to endocardial cushion defects), |
|
Down syndrome
screening |
↓ levels of α-fetoprotein,
↑β-hCG, ↑ nuchal translucency. |
|
Down syndrome
mech/and mom age |
95% of cases due to meiotic nondisjunction of homologous
chromosomes; associated with advanced maternal age - 4% of cases due to robertsonian translocation, - 1% of cases due to Down mosaicism (no maternal association) |
|
Edwards’ syndrome
findings |
severe mental retardation, rocker bottom feet, low-set ears, micrognathia (small jaw), congenital heart disease, clenched hands,
prominent occiput. Death usually occurs within 1 year of birth. |
|
severe mental retardation, rocker bottom feet, low-set ears, micrognathia (small jaw), congenital heart disease, clenched hands,
prominent occiput. |
Edwards’ syndrome
|
|
Patau’s syndrome
findings |
severe mental retardation, microphthalm microcephaly, cleft lip/palate, abnormal forebrain structures, polydactyly, congenital heart disease. Death usually occurs within 1 year of birth.
|
|
severe mental retardation, microphthalm microcephaly, cleft lip/palate, abnormal forebrain structures, polydactyly, congenital heart disease. Death usually occurs within 1 year of birth.
|
Patau’s syndrome
|
|
Congenital deletion of short arm of chromosome 5
(46,XX or XY, 5p−). |
Cri-du-chat
syndrome |
|
Cri-du-chat syndrome
genetics |
Congenital deletion of short arm of chromosome 5
(46,XX or XY, 5p−). |
|
Cri-du-chat syndrome
findings |
microcephaly, severe mental retardation, high-pitched crying/mewing, epicanthal folds,
cardiac abnormalities. |
|
microcephaly, severe mental retardation, high-pitched crying/mewing, epicanthal folds,
cardiac abnormalities. |
Cri-du-chat syndrome
|
|
22q11 syndrome
main |
CATCH-22.
Cleft palate, Abnormal facies, Thymic aplasia → T-cell deficiency, C ardiac defects, Hypocalcemia 2° to parathyroid aplasia, microdeletion at chromosome 22q11. Variable presentation as |
|
22q11 syndromes
Variable presentation as |
DiGeorge syndrome (thymic, parathyroid, and cardiac defects) or velocardiofacial syndrome (palate, facial, and cardiac defects).
|
|
Fetal alcohol syndrome
worst window |
3–8 weeks
|
|
Fetal alcohol syndrome
complications |
-pre- and postnatal developmental retardation, -microcephaly,
-facial abnormalities, -limb dislocation, -heart and lung fistulas. Mechanism may include |
|
Fetal alcohol syndrome
mech |
Mechanism may include
inhibition of cell migration. |
|
The number one cause of congenital malformations in
the United States. |
Fetal alcohol syndrome
|
|
Fetal alcohol syndrome
how common |
The number one cause of congenital malformations in
the United States. |
|
Chromosomal inversion nomenclature
|
PerIcentric: Involves the centromere, proceeds through meIosis
Paracentric. does NOT Involves the centromere, does NOT proceed through meiosis |